<DOC>
	<DOCNO>NCT00405418</DOCNO>
	<brief_summary>Primary objective : To demonstrate non-inferiority insulin glargine comparison insulin detemir term percentage patient reach target HbA1c &lt; 7 % end treatment period experience symptomatic hypoglycemia , confirm plasma glucose ( PG ) ≤ 56 mg/dL ( 3.1 mmol/L ) Secondary objective : - To compare 2 treatment group , percentage patient reach target HbA1c &lt; 7 % &lt; 6.5 % end treatment period - To compare change HbA1c fast plasma glucose ( FPG ) - To compare evolution blood glucose profile - To compare day day FPG variability , insulin dos - To determine treatment group biochemical patient-related determinant failure reach HbA1c target - To compare overall incidence rate symptomatic hypoglycemia nocturnal symptomatic hypoglycemia confirm PG ≤ 56 mg/dL ( 3.1 mmol/L ) - To compare treatment period , overall incidence rate symptomatic hypoglycemia symptomatic nocturnal hypoglycemia ( PG ≤ 70 mg/dL [ 3.9 mmol/L ] ) , symptomatic day-time hypoglycemia ( PG ≤ 70 mg/dL PG ≤ 56 mg/dL ) , severe hypoglycemia , asymptomatic hypoglycemia PG ≤ 56 mg/dL - To compare overall safety : incidence adverse event ( include serious hypoglycemia local tolerance injection site ) , change body weight , waist circumference waist / hip ratio - To assess quality life treatment satisfaction</brief_summary>
	<brief_title>Lantus Versus Levemir Treat-To-Target</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes least 1 year Insulin naïve Treated stable dos oral antidiabetic least 3 month prior study start , include least metformin ( least 1g/day ) 7 % ≤ HbA1c ≤ 10.5 % Body mass index ( BMI ) &lt; 40 kg/m² Ability willingness perform blood glucose monitoring use blood glucose meter use patient diary Type 1 diabetes Current previous use insulin ( except previous treatment gestational diabetes brief treatment insulin le 1 week ) Treatment glucagonlike peptide ( GLP ) 1 receptor agonist dipeptidyl peptidase ( DPP ) IV inhibitor Active proliferative diabetic retinopathy , define application photocoagulation surgery , 6 month study entry unstable ( rapidly progress ) retinopathy may require photocoagulation surgery study ( optic fundus examination perform 2 year prior study entry ) Pregnancy ( woman childbearing potential must negative pregnancy test study entry medically approve contraceptive method ) Breastfeeding History hypersensitivity study drug drug similar chemical structure Treatment systemic corticosteroid 3 month prior study entry Treatment investigational product 2 month prior study entry Likelihood require treatment study period drug permit clinical study protocol Clinically relevant cardiovascular , hepatic , neurological , endocrine , major disease make implementation protocol interpretation study result difficult Impaired hepatic function show Alamine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) great three time upper limit normal range study entry Impaired renal function show serum creatinine ≥ 1.5 mg/dL ( ≥ 133 μmol/L ) men ≥ 1.4 mg/dL ( 124 μmol/L ) woman study entry History drug alcohol abuse last year The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>